An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.
• Treatments: Irinotecan

Criteria

Inclusion Criteria:

• Metastatic colorectal cancer (adenocarcinoma)

• UGT1A1 genotyped patients

• Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents)

Exclusion Criteria:

• Contraindication of CPT-11

• Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) 3-4

• Patients to receiving CPT-11 as adjuvant chemotherapy

• History of pelvic irradiation